June 26th, 2023

XPeng Inc. (NYSE: XPEV), a leading Chinese electric vehicle manufacturer, is poised to have a significant impact on the automotive market with the highly anticipated launch of its XPENG G6 Ultra Smart Coupe SUV. This revolutionary vehicle, developed . Read more

June 26th, 2023

Shares of Lucid Group, Inc. (Nasdaq: LCID) surged over 5% in pre-market trading after announcing a long-term strategic technology partnership with Aston Martin. The partnership involves the integration and supply of Lucid's advanced electric vehic. Read more

June 26th, 2023

Several companies are set to release their financial results on Thursday, June 29, including: NIKE, Inc. (NYSE: NKE), a global sports apparel and footwear giant, will unveil its fourth-quarter fiscal 2023 financial results after regular trading ho. Read more

June 25th, 2023

The U.S. Coast Guard said it has initiated a Marine Board of Investigation (MBI) following the tragic incident involving the Titan submersible and its five occupants. The crew of the Polar Prince research vessel lost communication with the Titan subm. Read more

June 25th, 2023

Exact Sciences Corporation (Nasdaq: EXAS) was maintained with a Buy rating by Canaccord Genuity, who raised the price target from $92 to $115.  On Friday, $EXAS closed at $92.62, indicating a potential upside of $22.38 or 24.16% based on the . Read more

June 25th, 2023

The results from a phase 3 clinical trial evaluating Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in individuals with obesity or overweight and type 2 diabetes demonstrated superior weight reduction . Read more

June 25th, 2023

Several companies are expected to report their financial results on Wednesday, June 28, including: BlackBerry Limited (NYSE: BB), a global leader in secure communication and software solutions, is scheduled to release its first-quarter fiscal year. Read more

June 25th, 2023

DexCom, Inc. (Nasdaq: DXCM) is making significant strides in its financial performance, leading the company to update its year-end 2025 revenue targets. With strong performance in the first two years of the target period, DexCom now expects to achiev. Read more

June 25th, 2023

Pfizer Inc. (NYSE: PFE) has received FDA approval for LITFULO (ritlecitinib), an oral treatment for severe alopecia areata in individuals aged 12 and above. LITFULO, which is expected to be available in the coming weeks, is the first and only FDA-app. Read more

June 24th, 2023

The U.S. Food and Drug Administration (FDA) has released its first draft guidance on conducting clinical trials with psychedelic drugs for potential medical treatment. Published on June 23, 2023, the guidance aims to provide researchers with importan. Read more